Actavis prepares bid for Merck KgaA's generic drugs ops |
|
|
|
Published
:
Fri, 26 Jan 2007 11:33
|
FRANKFURT (AFX) - Icelandic generic drugs company Actavis Group HF is interested in acquiring Merck KgaA's generic drugs ops, reported Financial Times, citing Actavis's CEO Robert Wessman.'We are preparing a bid,' Wessman told the newspaper, adding: 'Financing for a due diligence is in place.'A successful deal would make Actavis the world's third largest generic drug company, the newspaper noted.Rival company Ranbaxy Laboratories Ltd aims to start due diligence procedures next month on Merck's generic drugs unit, which it is considering bidding for in conjunction with private equity firms.krysia.diver@afxnews.comkd/jagCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
Print this Story
Merck KGaA says 6.2 mln new shares placed at 87.00 eur/shr UPDATE 